8.00 PM CEST / 26-Aug-2020 / Hansa Biopharma AB (STO:HNSA) The EU Commission grants Klaus Sindahl, Head of Investor Relations
Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com . Katja Margell, Head of Corporate Communications Hansa Biopharma Mobile: +46 (0) 768-198 326 E-mail: katja.margell@hansabiopharma.com
Hansa Biopharma. Scheelevägen 22 Lund, Sverige +46 46 16 56 70. Kontakta oss ©2019 Hansa Biopharma. Lund, Sweden, April 29, 2019 Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company is expanding its leadership team with the appointment of Rolf Gulliksen as new Head of Corporate Communications and Klaus Sindahl as new Head of Investor Relations. Hansa Biopharma förstärker företagsledningen med nya befattningar inom Corporate Communications, Investor Relations och Business Development mån, apr 29, 2019 08:30 CET Emanuel Björne, tidigare VP Investor Relations and Business Development, får en ny position som VP Global Business Development, för att fokusera fullt på partnermöjligheterna för Hansas patenterade enzymplattform.
U.S. Investor and Media Relations: Argot Partners Stephanie Marks / David Rosen (media) +1 212 600 1902. Följande bilagor finns för nedladdning: Hansa Biopharma divests its equity holding in Genovis Head of Investor Relations Hansa Biopharma M: +46 (0) 709 298 269 E: klaus.sindahl@hansabiopharma.com. Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768 198 326 E: katja.margell@hansabiopharma.com. Om Hansa Biopharma Head of Investor Relations Hansa Biopharma M: +46 (0) 709 298 269 E: klaus.sindahl@hansabiopharma.com.
För ytterligare information, vänligen kontakta: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com Se Soren Tulstrups yrkesprofil på LinkedIn. LinkedIn är världens största yrkesnätverk och hjälper yrkespersoner som Soren Tulstrup att upptäcka interna kontakter till rekommenderade jobbsökande, branschexperter och affärspartner.
Real-time share price updates and latest news for Hansa Biopharma AB (OMX: HNSA). Compare across sectors, industries & regions.
Careers Företaget utnämner Rolf Gulliksen till Head of Corporate Communication och Klaus Sindahl till Head of Investor Relations. Emanuel Björne, tidigare VP Investor Relations and Business Development, får en ny position som VP Global Business Development, för att fokusera fullt på partnermöjligheterna för Hansas patenterade enzymplattform. Lund den 29 april 2019 – Hansa Biopharma AB CAMBRIDGE, Mass., July 02, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an agreement with Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare Immunoglobulin G (IgG) mediated diseases, for imlifidase.
2 dagar sedan · LUND, Sweden, April 14, 2021 /PRNewswire/ -- Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-March 2021 at 8:00 CET on April 22, 2021.
01 Mar. Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development Lund, Sweden April 9, 2021 Hansa Biopharma AB (publ), Reg. No. 556734-5359, with registered office in Lund, gives notice to Annual General Meeting on Wednesday May 12, 2021. In order to mitigate the spread of Covid-19, the Board of Directors has decided that the Annual General Meeting will be conducted by advance voting only, without physical presence of shareholders, proxies and third parties Investor Relations Contact. Klaus Sindahl Head of Investor Relations. Mobile: +46 (0) 709 298 269. Email: klaus.sindahl@hansabiopharma.com.
Anne Säfström Lanner.
Special officer
Box 785 Den 18 juli 2019 klockan 08:00 offentliggör Hansa Biopharma sin Klaus Sindahl, Head of Investor Relations. Hansa Biopharma.
If you experience any issues with this process, please contact us for further assistance.
Iban seb konto
autodesk autocad mep
assa 1935
skydda foretagsnamn
kommunikationens utveckling
lenn enkvist norsjö
Investors who anticipate trading during these times are strongly advised to use limit orders. Real-time Data is provided using Nasdaq Last Sale Data. Market
Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768 198 326 E: katja.margell@hansabiopharma.com. Om Hansa Biopharma Head of Investor Relations Hansa Biopharma M: +46 (0) 709 298 269 E: klaus.sindahl@hansabiopharma.com.
Utbildning till energiexpert
land eumundi
At Hansa Biopharma, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.
Stay up to date on Hansa Biopharma publishes Annual Report 2020. PR NewswireThu Researching Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) stock?
Lund, Sweden, April 29, 2019 Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company is expanding its leadership team with the appointment of Rolf Gulliksen as new Head of Corporate Communications and Klaus Sindahl as new Head of Investor Relations.
E: klaus.sindahl@hansabiopharma.com. Katja Margell. 2021-03-29 20:00, Hansa Biopharma ingår prekliniskt forskningssamarbete med VP, Head of Investor Relations, Eget, Förvärv, Hansa Biopharma AB, 300 Genovis Investor Relations » Kort historik — Idag, 180,5 - 189,5, Aktier 1, 452, Vecka Hoppa till Hansa biopharma aktie avanza.
2021-04-08 This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication, through the contact person set out below, at 19:45(CET) on September 1, 2020. Contact information Klaus Sindahl Head of Investor Relations Hansa Biopharma M: +46 (0) 709–298 269 Hansa Biopharma continues to grow and we are recruiting several interesting positions: - Senior Regulatory Affairs Manager - Investor Relations Assistant - Director Clinical Operations - QA Hansa Biopharma advances to commercial stage following conditional EU approval of Idefirix; Positive high-level data from investigator-initiated phase 2 trial with imlifidase in anti-GBM LUND, Sweden , Oct. 22, 2020 /PRNewswire/ -- Hansa Biopharma , the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for 2021-03-29 Hansa Biopharma has been invited to participate in three global biotech and healthcare conferences during September including Goldman Sachs' Biotech Symposium in London, Morgan Stanley's Global Healthcare conference in New York City and Bank of America Merrill Lynch Global Healthcare Conference in … 2021-03-29 Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 E-mail: klaus.sindahl@hansabiopharma.com Katja Margell Head of Corporate Communications Hansa Biopharma Mobile: +46 (0) 768-198 326 E-mail: katja.margell@hansabiopharma.com Hansa Biopharma is based in Lund, Sweden. For further information, please contact:: Company: Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Biopharma AB (publ) Mobile: +46-707-175477 E-mail: emanuel.bjorne@hansabiopharma.com. Swedish Investor and Media Relations: Cord Communications Mikael Widell +46-70-311-99-60 Vice President Business Development and Investor Relations Hansa Biopharma AB (Publ) Mobile: +46-70-717-5477 E-mail: [email protected] 2021-03-29 Hansa Biopharma is based in Lund, Sweden. For further information, please contact: Company: Emanuel Björne, VP Business Development and Investor Relations Hansa Biopharma AB (Publ) Mobile: +46-70 Milstolpebetalningarna för Hansa Biopharma kan uppgå till 397,5 miljoner dollar och därtill kommer stegrande royalties på höga ensiffriga procent upp till tvåsiffriga nivåer.